Scienture Holdings, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SCNX Nasdaq 2834 scienture.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scienture Holdings, Inc.

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - Feb 3rd, 2026 6:05 am
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment - Jan 14th, 2026 6:05 am
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA - Dec 22nd, 2025 6:05 am
Scienture, BlinkRx announce strategic collaboration to expand access to Arbli - Dec 11th, 2025 6:20 am
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - Dec 10th, 2025 6:05 am
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Dec 8th, 2025 7:00 am
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 - Dec 2nd, 2025 6:05 am
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Dec 1st, 2025 7:00 am
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update - Nov 13th, 2025 6:05 am
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction - Nov 13th, 2025 5:50 am
Scienture Holdings: Q3 Earnings Snapshot - Nov 12th, 2025 3:49 pm
BC-Most Active Stocks - Nov 4th, 2025 8:30 am
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans - Nov 4th, 2025 6:05 am
EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives - Nov 4th, 2025 5:51 am
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium) - Oct 23rd, 2025 6:05 am
EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients - Oct 23rd, 2025 5:51 am
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers - Oct 16th, 2025 7:00 am
SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet - Oct 8th, 2025 7:00 am
SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions - Oct 1st, 2025 7:00 am
EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions - Oct 1st, 2025 6:46 am